Historical Valuation
Biodesix Inc (BDSX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.51 is considered Undervalued compared with the five-year average of -4.28. The fair price of Biodesix Inc (BDSX) is between 6.56 to 55.31 according to relative valuation methord. Compared to the current price of 5.79 USD , Biodesix Inc is Undervalued By 11.73%.
Relative Value
Fair Zone
6.56-55.31
Current Price：5.79
11.73%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Biodesix Inc (BDSX) has a current Price-to-Book (P/B) ratio of -29.84. Compared to its 3-year average P/B ratio of -3.12 , the current P/B ratio is approximately 855.31% higher. Relative to its 5-year average P/B ratio of 0.62, the current P/B ratio is about -4895.98% higher. Biodesix Inc (BDSX) has a Forward Free Cash Flow (FCF) yield of approximately -56.73%. Compared to its 3-year average FCF yield of -41.23%, the current FCF yield is approximately 37.60% lower. Relative to its 5-year average FCF yield of -37.47% , the current FCF yield is about 51.39% lower.
P/B
Median3y
-3.12
Median5y
0.62
FCF Yield
Median3y
-41.23
Median5y
-37.47
Competitors Valuation Multiple
AI Analysis for BDSX
The average P/S ratio for BDSX competitors is 1.29, providing a benchmark for relative valuation. Biodesix Inc Corp (BDSX.O) exhibits a P/S ratio of 0.51, which is -60.31% above the industry average. Given its robust revenue growth of 19.93%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BDSX
1Y
3Y
5Y
Market capitalization of BDSX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BDSX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BDSX currently overvalued or undervalued?
Biodesix Inc (BDSX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.51 is considered Undervalued compared with the five-year average of -4.28. The fair price of Biodesix Inc (BDSX) is between 6.56 to 55.31 according to relative valuation methord. Compared to the current price of 5.79 USD , Biodesix Inc is Undervalued By 11.73% .
What is Biodesix Inc (BDSX) fair value?
BDSX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Biodesix Inc (BDSX) is between 6.56 to 55.31 according to relative valuation methord.
How does BDSX's valuation metrics compare to the industry average?
The average P/S ratio for BDSX's competitors is 1.29, providing a benchmark for relative valuation. Biodesix Inc Corp (BDSX) exhibits a P/S ratio of 0.51, which is -60.31% above the industry average. Given its robust revenue growth of 19.93%, this premium appears unsustainable.
What is the current P/B ratio for Biodesix Inc (BDSX) as of Jan 09 2026?
As of Jan 09 2026, Biodesix Inc (BDSX) has a P/B ratio of -29.84. This indicates that the market values BDSX at -29.84 times its book value.
What is the current FCF Yield for Biodesix Inc (BDSX) as of Jan 09 2026?
As of Jan 09 2026, Biodesix Inc (BDSX) has a FCF Yield of -56.73%. This means that for every dollar of Biodesix Inc’s market capitalization, the company generates -56.73 cents in free cash flow.
What is the current Forward P/E ratio for Biodesix Inc (BDSX) as of Jan 09 2026?
As of Jan 09 2026, Biodesix Inc (BDSX) has a Forward P/E ratio of -2.25. This means the market is willing to pay $-2.25 for every dollar of Biodesix Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Biodesix Inc (BDSX) as of Jan 09 2026?
As of Jan 09 2026, Biodesix Inc (BDSX) has a Forward P/S ratio of 0.51. This means the market is valuing BDSX at $0.51 for every dollar of expected revenue over the next 12 months.